Clinical trial · Observational
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
NCT06054529CI-TRIAL-00087179GBM-FLUX2active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| d4-NAM infusion | Other | — | UNRESOLVED |
| Surgical removal of the GBM tumor | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants in surgery
- description
- Surgical removal of the GBM tumor.
- interventionNames
- Procedure: Surgical removal of the GBM tumor
- Other: d4-NAM infusion
Primary outcomes (1)
- measure
- Subtyping of GBM tumors as Classical, Proneural or MES (based on RNA-seq)
- timeFrame
- 2 months
- description
- Resected tumor tissue will undergo routine testing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Preoperative MRI consistent with a primary intracranial malignant brain tumor. 2. Must be 18 years of age or older. 3. Patient eligible for debulking surgery/resection. Exclusion Criteria: 1. Inability to obtain pre-operative IV access. 2. Use of Tru Niagen, Basis (or any other nicotinamide riboside (NR)-containing NAD+ booster) or niacin supplements within one month prior to Study Visit 1. 3. Participation in studies involving investigational drug(s) within 30 days prior to Study Visit 1 4. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Study Visit 1 (participants may not donate blood any time during the study, through the final study day) 5. Presence of any condition that, in the opinion of Dr. Field, compromises participant safety or data integrity or the participant's ability to complete study days. 6. Pregnancy, lactation or \< 9 months postpartum from the Study Visit 1 date.
References
Publications (0)
Data not yet available
No reference posted for this study.